Literature DB >> 1737400

Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.

T Ito1, T Seyama, T Mizuno, N Tsuyama, T Hayashi, Y Hayashi, K Dohi, N Nakamura, M Akiyama.   

Abstract

Thyroid neoplasms show a wide variety of lesions varying from slowly growing differentiated adenocarcinomas to rapidly proliferating undifferentiated carcinomas. There has been some histopathological evidence that the undifferentiated thyroid carcinomas are derived from differentiated carcinomas. Moreover, it is suspected that some genetic events might be associated with such changes. In the present study, mutations in the p53 gene were investigated by direct sequencing analysis after polymerase chain reaction amplification of exons 5 to 8, using paraffin-embedded primary tumors and cultured cells. No mutations in exons 5 to 8 were detected in 10 differentiated papillary adenocarcinomas, whereas 6 of 7 undifferentiated carcinomas were found to carry base substitution mutations. Sequencing analysis confirmed mutations at codons 135 (TGC----TGT), 141 (CCC----CCT), 178 (CAC----GAC), 213 (CGA----TGA), 248 (CGG----CAG, CGG----TGG), and 273 (CGT----TGT). The spectrum of mutations (G:C to A:T transitions in 7 of 8) might be a specific feature of the spontaneous cancers. The results strongly suggest that, in human thyroid glands, p53 mutations play a crucial role in the progression of differentiated carcinomas to undifferentiated ones.

Entities:  

Mesh:

Year:  1992        PMID: 1737400

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

1.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.

Authors:  Liliána Z Fehér; Gábor Pocsay; László Krenács; Agnes Zvara; Enikő Bagdi; Réka Pocsay; Géza Lukács; Ferenc Győry; Andrea Gazdag; Erzsébet Tarkó; László G Puskás
Journal:  Pathol Oncol Res       Date:  2011-12-11       Impact factor: 3.201

3.  Possible Relation of p53 and mdm-2 Oncoprotein Expression in Thyroid Carcinoma: A Molecular-Pathological and Immunohistochemical Study on Paraffin-Embedded Tissue.

Authors:  Kurt W. Schmid; Agnes Bankfalvi; Swantja Mucke; Dietmar Ofner; Kristina Riehemann; Soren Schroder; Andrea Stucker; Martin Totsch; Barbara Dockhorn-Dworniczak
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

Review 4.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

5.  Chromothripsis: breakage-fusion-bridge over and over again.

Authors:  Carlos Oscar Sánchez Sorzano; Alberto Pascual-Montano; Ainhoa Sánchez de Diego; Carlos Martínez-A; Karel H M van Wely
Journal:  Cell Cycle       Date:  2013-06-11       Impact factor: 4.534

Review 6.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

Review 7.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

Review 8.  Pax-8-PPAR-γ fusion protein in thyroid carcinoma.

Authors:  Priyadarshini Raman; Ronald J Koenig
Journal:  Nat Rev Endocrinol       Date:  2014-07-29       Impact factor: 43.330

9.  Clinicopathological findings and p53 expression of thyroid cancer in children.

Authors:  T Kobayashi; H Nakanishi; I Yana; I Nishisho; Y Itoh; E Wakasugi; T Takeda; T Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

10.  Anaplastic thyroid cancer and hyperthyroidism.

Authors:  Vijay Kumar; Bruno Blanchon; Xin Gu; Marjorie Fowler; David Scarborough; Cherie Ann Nathan; Subhashini Yaturu
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.